Arvinas (ARVN)
(Delayed Data from NSDQ)
$35.23 USD
0.00 (0.00%)
Updated May 24, 2024 04:00 PM ET
After-Market: $35.55 +0.32 (0.91%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 141 - 160 ( 205 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Update: Strong Cash Position with Exciting Catalysts Before YE2020
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Ahead of ARV-471 Data Readout in 4Q20; Reit Buy and $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Two Key Clinical Data Updates Expected in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Data Represents a Better-Case Scenario in Our Mind
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-110 ASCO Presentation: ?110 Working as Designed
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
CORRECTED: ASCO Virtual Meeting Abstract Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Abstract - Several Datapoints Have Us Very Bullish. Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z